GET DAILY SIGNALSAdvisorShares Psychedelics ETF (PSIL) Declines -9% as Biotech Headwinds Persist
Key Takeaways
- PSIL is an actively managed thematic ETF providing exposure to the emerging global psychedelic-medicine industry, with essentially all of its portfolio concentrated in the healthcare sector.
- The fund holds roughly 30 to 35 mostly small- and micro-cap life sciences companies, with Compass Pathways, Definium Therapeutics, Atai Beckley, Relmada Therapeutics, and NRx Pharmaceuticals among its largest positions.
- PSIL declined approximately 9% over the trailing month, reflecting a broad pullback across speculative biotech and small-cap growth names.
- The fund carries a net expense ratio of approximately 1.00% and a non-diversified structure, consistent with a niche, actively managed thematic vehicle.
- Elevated interest rates and a risk-off tone toward pre-revenue biotechnology remain the dominant macro headwinds for the strategy.
- Key risks include binary clinical-trial outcomes, regulatory uncertainty, and limited liquidity in underlying holdings.
PSIL ETF Overview
The AdvisorShares Psychedelics ETF is an actively managed exchange-traded fund launched in September 2021. Under normal circumstances, the fund invests at least 80% of its net assets in securities of companies that derive a meaningful share of revenue from, or devote substantial assets to, psychedelic drugs, alongside derivatives with similar economic characteristics. The portfolio primarily targets publicly listed life sciences companies developing psychedelic medicines, but it also includes related businesses operating across the broader psychedelics ecosystem.
PSIL is a non-diversified, single-sector vehicle with effectively 100% of assets allocated to healthcare. It holds roughly 30 to 35 positions, blending pure-play psychedelic drug developers with larger, more established pharmaceutical companies. Core holdings have included Compass Pathways, Definium Therapeutics, Atai Beckley, Relmada Therapeutics, and NRx Pharmaceuticals, alongside positions in companies such as Neurocrine Biosciences, Cybin, and GH Research. The net expense ratio is approximately 1.00%. Given the small average market capitalization of its underlying names, PSIL behaves more like a concentrated, early-stage biotech portfolio than a broad equity fund. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the healthcare space.
Industry and Thematic Landscape
The psychedelic-medicine theme sits at the intersection of psychiatry, neuroscience, and novel drug development. Companies in this space are pursuing therapies derived from compounds such as psilocybin, MDMA, and related molecules to treat conditions including treatment-resistant depression, post-traumatic stress disorder, and other mental-health disorders. The investment case rests on a sizable unmet clinical need and early, often promising, trial data, but commercialization remains largely unproven.
The broader environment has been challenging for early-stage biotechnology. Higher-for-longer interest rates reduce the present value of distant cash flows and raise the cost of capital, pressuring pre-revenue companies that depend on equity financing to fund multi-year clinical programs. Regulatory review of psychedelic compounds has also been uneven, with mixed clinical outcomes and cautious signals from health authorities. These structural factors mean the theme is characterized by high volatility, binary catalysts, and concentrated risk rather than steady, diversified growth. From what I see, this remains the core challenge for the sector.
Performance and Positioning Snapshot
PSIL has been volatile over recent months. After a rally that carried the fund toward a late-summer peak around $27, the ETF gave back much of its 2026 gains and declined roughly 9% over the trailing month to trade near $21. The move has been trend-driven rather than range-bound, reflecting a broader de-rating of speculative, small-cap biotech rather than fund-specific news.
Because the portfolio is concentrated in a handful of clinical-stage developers, its performance has been closely tied to the fortunes of its largest holdings. Compass Pathways and Atai Beckley, both leaders in psilocybin and other psychedelic programs, and smaller developers such as Relmada Therapeutics have experienced pronounced swings as trial readouts, financing activity, and shifting investor sentiment reshaped expectations. The presence of larger pharmaceutical names provides only limited ballast given the small size of the overall fund and the dominance of the healthcare theme. I’m watching this closely as the next set of catalysts approaches.
2026 Outlook and Key Factors to Monitor
The trajectory of PSIL over the remainder of 2026 will likely hinge on several structural factors. Clinical trial results and regulatory decisions for psychedelic-based therapies remain the most consequential catalysts, as positive data could re-rate the entire theme while disappointing outcomes carry concentrated downside risk. The interest-rate environment and the availability of capital for early-stage biotech will continue to shape financing conditions for portfolio companies, many of which require repeated equity raises.
Investors should also monitor regulatory policy toward psychedelic compounds, competitive developments among leading developers, and the potential for consolidation as larger pharmaceutical companies evaluate the space. Institutional fund flows into thematic and biotech ETFs, alongside overall risk appetite, will influence near-term price action. While the long-term addressable market in mental health is substantial, the path to commercialization is uncertain, and the fund’s concentrated, non-diversified structure amplifies both the opportunity and the risk. No price predictions are made here; these are simply the key themes likely to drive the ETF in the months ahead.
Exploring Themes with Tickeron’s AI Screener
In my research on niche areas like psychedelic medicine, I frequently rely on Tickeron’s AI Screener to scan for comparable holdings and assess sector trends alongside technical signals. The platform lets users apply customizable filters across industries and quantitative metrics, which helps surface relevant opportunities without manual effort. It has become a practical part of how I evaluate concentrated thematic funds like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PSIL sees its Stochastic Oscillator ascending out of oversold territory
On October 21, 2026, the Stochastic Oscillator for PSIL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In 59 of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PSIL's RSI Oscillator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on PSIL as a result. In 75 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for PSIL just turned positive on October 21, 2026. Looking at past instances where PSIL's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
Following a +1.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where PSIL advanced for three days, in 258 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
PSIL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
PSIL moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PSIL crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PSIL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PSIL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category MiscellaneousSector
Advertisement